A carregar...
Novel Therapies in Advanced Renal Cell Carcinoma: Management of Adverse Events From Sorafenib and Sunitinib
INTRODUCTION: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. METHODS: Selective review in Medline and the data base of...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Deutscher Arzte Verlag
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2696772/ https://ncbi.nlm.nih.gov/pubmed/19629201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3238/arztebl.2008.0232 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|